Fig. 3.

a Cell viability of COS following 24–48 h of treatment with 12.5 μM 5HT (2nd bar, *, p < 0.05; n = 6), 1.0 nM GnRH (3rd bar, *, p < 0.05; n = 6), 1.0 nM GnRH with 10.0 nM Teverelix (GnRHR inhibitor; 4th bar), or GnRH and 5HT co-treatment (last bar, **, p < 0.01; n = 6). b Cell viability of COS (as % of DMSO control) following increasing doses of either 5HT alone (grey line) or GnRH+5HT (black line). c Cell viability of COS following 24 h of treatment with 10 nM kisspeptin, 10 nM Teverelix, 10 nM each Kisspeptin+Teverelix, 1.0 nM GnRH, or 1.0 nM GnRH + 10 nM Teverelix (**, p < 0.01; n = 6; ***, p < 0.001; n = 6)